No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > PARP Inhibitor Therapy

Toggle Menu

PARP Inhibitor Therapy

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

PARP inhibitors for breast cancer

Metastatic breast cancer

Lynparza and Talzenna are targeted therapies known as PARP inhibitors. Both agents have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation. BRACAnalysis CDx—a companion diagnostic test—received approval at the same time as the agents. The National Comprehensive Cancer Network (NCCN) has added both agents as a preferred single agent treatment for people with advanced breast cancer and a BRCA mutation. 

Breast cancer clinical trials 

Research is now also looking at PARP inhibitor effectiveness in additional settings including:

  • patients with metastatic breast cancer who have other inherited mutations beyond BRCA1 and BRCA2, such as ATM and PALB2
  • as adjuvant or neoadjuvant treatment for patients with earlier stage breast cancer
  • patients with triple-negative metastatic breast cancer
  • PARP inhibitors in combination with other agents, such as drugs that shrink blood supply and immunotherapies.

You can look for research studies enrolling patients with breast cancer by visiting FORCE's Research Study Search Tool.


Updated 03/25/2019

FORCE:Facing Our Risk of Cancer Empowered